PMID- 15980695
OWN - NLM
STAT- MEDLINE
DCOM- 20050913
LR  - 20200930
IS  - 1525-4135 (Print)
IS  - 1525-4135 (Linking)
VI  - 39
IP  - 3
DP  - 2005 Jul 1
TI  - The impact of incident and prevalent herpes simplex virus-2 infection on the 
      incidence of HIV-1 infection among commercial sex workers in South Africa.
PG  - 333-9
AB  - This study investigated the impact of prevalent and incident HSV-2 infection on 
      the incidence of HIV-1 infection in a cohort of female commercial sex workers in 
      KwaZulu-Natal, South Africa. Prior to a vaginal microbicide trial, 416 women were 
      screened for antibodies to HIV-1 and herpes simplex virus-2 (HSV-2) infections 
      and a questionnaire was used to establish behavioral, social, and demographic 
      characteristics. A total of 187 HIV-1-seronegative women were followed up at 
      monthly intervals when blood was drawn and used to detect HIV-1 and HSV-2 
      antibodies. The median duration of follow-up was 2.2 years. At screening 50% of 
      the women were HIV-1 seropositive and 84% were HSV-2 seropositive. The hazards of 
      HIV-1 among women who were HSV-2 seropositive or seronegative throughout, or 
      among those who seroconverted during the study, were not significantly different. 
      When HSV-2 seroconversion was analyzed as a time-dependent covariate, the hazard 
      ratio for HIV-1 seroconversion was 6.0 (95% CI: 2.6-14.0) times greater among 
      women with incident than among women with prevalent HSV-2 infections. Drawing on 
      other recent studies these data suggest that incident HSV-2 infection increases 
      the risk of HIV-1 infection; the effect wanes with time since infection; and the 
      effect is significantly greater for men than it is for women.
FAU - Ramjee, Gita
AU  - Ramjee G
AD  - HIV-1 Prevention Research Unit, Medical Research Council, Durban, South Africa.
FAU - Williams, Brian
AU  - Williams B
FAU - Gouws, Eleanor
AU  - Gouws E
FAU - Van Dyck, Eddy
AU  - Van Dyck E
FAU - De Deken, Benedicte
AU  - De Deken B
FAU - Karim, Salim Abdool
AU  - Karim SA
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Vaginal Creams, Foams, and Jellies)
RN  - 26027-38-3 (Nonoxynol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Infective Agents/administration & dosage
MH  - Female
MH  - HIV Infections/*complications/*epidemiology/prevention & control/transmission
MH  - HIV Seropositivity
MH  - *HIV-1
MH  - Herpes Genitalis/*complications/epidemiology/prevention & control
MH  - *Herpesvirus 2, Human
MH  - Humans
MH  - Middle Aged
MH  - Nonoxynol/administration & dosage
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - *Sex Work
MH  - South Africa/epidemiology
MH  - Time Factors
MH  - Vaginal Creams, Foams, and Jellies
EDAT- 2005/06/28 09:00
MHDA- 2005/09/15 09:00
CRDT- 2005/06/28 09:00
PHST- 2005/06/28 09:00 [pubmed]
PHST- 2005/09/15 09:00 [medline]
PHST- 2005/06/28 09:00 [entrez]
AID - 00126334-200507010-00012 [pii]
AID - 10.1097/01.qai.0000144445.44518.ea [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):333-9. doi: 
      10.1097/01.qai.0000144445.44518.ea.